Publication for FDPS and HMGCS1
| Species | Symbol | Function* | Entrez Gene ID* | Other ID | Gene coexpression |
CoexViewer |
|---|---|---|---|---|---|---|
| hsa | FDPS | farnesyl diphosphate synthase | 2224 |  |
[link] | |
| hsa | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 | 3157 | |
| Pubmed ID | Priority | Text |
|---|---|---|
| 26535575 | 0.98 | HMGCS1, FDPS, HMGCR, and ACAT2. |
| 0.91 | HMGCS1, TMEM97, TM7SF2, FDFT1, ACAT2, EBP, FDPS, HMGCR, SQLE, DHCR7, C14orf1, and INSIG1. | |
| 0.90 | HMGCS1, TMEM97, ACAT2, HMGCR, SC4MOL, FDPS, SQLE, CDK5RAP2, and INSIG1. | |
| 0.85 | HMGCS1, TM7SF2, FDFT1, EBP, FDPS, HMGCR, SQLE, and DHCR7. | |
| 30321984 | 0.98 | HMGCS1), HMG-CoA reductase (HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase (MVD). |
| 0.97 | HMGCS1, HMGCR, mevalonate diphosphate decarboxylase (MVD), FDPS, and 7-dehydrocholesterol reductase (DHCR7) expression, by simvastatin was significantly decreased by 20 muM emodin in SK-HEP-1 (Figure 4B) and HepG2 (Figure 4C) cells. | |
| 0.87 | HMGCS1, HMGCR, and FDPS, were decreased by emodin in SK-HEP-1 cells in a dose-dependent manner (Figure 4D). | |
| 0.85 | HMGCS1, HMGCR, FDPS, DHCR7, and DHCR24 after treatment of HCC cells with emodin and sorafenib. | |
| 17052361 | 0.98 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) (5.6, p = 0.000009), fatty acid synthase (FASN) (5.4, p = 0.000008), 7-dehydrocholesterol reductase (DHCR7) (4.3, p = 0.000008), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (3.1, p = 0.00001), sterol-C5-desaturase like (SC5DL) (3.1, p = 0.00001), acetyl-CoA acetyltransferase 2 (also termed acetoacetyl-CoA thiolase; ACAT2) (3.0, p = 0.00009), low density lipoprotein receptor (LDLR) (2.8, p = 0.00001) and farnesyl diphosphate synthase (FDPS) (2.8, p = 0.000009). |
| 0.91 | HMGCS1, HMGCR, FDPS, SC5DL and DHCR7; see legend to Fig. 1 for complete names), cholesterol transport (LDLR) and fatty acid biosynthesis (FASN and SCD1). | |
| 26646011 | 0.98 | HMGCS1, HMG-CoA synthase 1; HMGCR, HMG-CoA reductase; FDPS, farnesyl diphosphate synthase; SQLE, squalene epoxidase; LSS, lanosterol synthase; NSDHL, NAD(P)-dependent steroid dehydrogenase-like; DHCR24, 24-dehydrocholesterol reductase; SC5D, sterol-C5-desaturase; DHCR7, 7-dehydrocholesterol reductase. |
| 0.95 | HMGCS1, HMG-CoA synthase 1; HMGCR, HMG-CoA reductase; MVK, mevalonate kinase; PMVK, phosphomevalonate kinase; MVD, mevalonate decarboxylase; IDI1, isopentenyl-diphosphate delta isomerase 1; FDPS, farnesyl diphosphate synthase; FDFT1, farnesyl-diphosphate farnesyltransferase 1; SQLE, squalene epoxidase; LSS, lanosterol synthase; CYP51A1, cytochrome P450 family 41 subfamily A; TM7SF2, transmembrane 7 superfamily member 2; NSDHL, NAD(P)-dependent steroid dehydrogenase-like; HSD17B7, hydroxysteroid 17-beta dehydrogenase; DHCR24, 24-dehydrocholesterol reductase; SC5D, sterol-C5-desaturase; DHCR7, 7-dehydrocholesterol reductase. | |
| 30333528 | 0.98 | FDPS, and HMGCS1 (Fig. 2e). |
| 0.83 | HMGCS1, HMGCR, FDPS, and FDFT1 in sphere cells compared with their differentiated counterparts (Fig. 2f). | |
| 21858874 | 0.98 | Fdps, Hmgcs1) and fatty acid biosynthesis (Acsl3, Acsl4, Fasn) (Table 2), suggesting that mTOR induces expression of multiple proteins necessary for myelin lipid synthesis. |
| 26519296 | 0.98 | Fdps which have been genotype-associated with higher HDL-C levels and NAFLD in humans, respectively; b) Hmgcs1 which has been shown to be positively associated with HDL-C levels; and c) Insig1 which is a gene that, when overexpressed in livers of Zucker diabetic fatty rats, attenuates hepatic steatosis. |
| 26535009 | 0.98 | HMGCS1, DHCR7, DHCR24, LDLR, FDFT1, FDPS, IDI1, MVD, SQLE, LSS, NSDHL, SC5DL, INSIG1, ACLY, and ACSS2 (see fig. S1 for full list). |
| 29849100 | 0.98 | 3-hydroxy-3-methylglutaryl-coa synthase 1 - HMGCS1, 3-hydroxy-3-methylglutaryl-coa reductase -HMGCR, Cytochrome P450, family 51, subfamily A, polypeptide 1 - CYP51A1, Fatty acid desaturase 1 - FADS1, Hydroxysteroid (17-beta) dehydrogenase 8 - HSD17B8, Isopentenyl-diphosphate delta isomerase 1 - IDI1, Aldolase C, fructose-bisphosphate - ALDOC, Acyl-coa synthetase short-chain family member 2 - ACSS2, ATP citrate lyase - ACLY, Hydroxysteroid (17-beta) dehydrogenase 7 - HSD17B7, Farnesyl diphosphate synthase - FDPS, Farnesyl-diphosphate farnesyltransferase 1 - FDFT1, Mevalonate kinase - MVK, NAD(P) dependent steroid dehydrogenase-like - NSDHL, FK506 binding protein 4 - FKBP4, Retinol dehydrogenase 11 - RDH11, Pantothenate kinase 3 - PANK3, Hydroxysteroid (17-beta) dehydrogenase 12 - HSD17B12, Atpase family, AAA domain containing 2 - ATAD2, Thymidylate synthetase - TYMS, Prenyl (decaprenyl) diphosphate synthase, subunit 1 - PDSS1, Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 - CHST6 and NADH dehydrogenase (ubiquinone) flavoprotein 2 -NDUFV2) and purmorphamine treatment group (NADPH oxidase 4 - NOX4, Cytochrome P450, family 26, subfamily B, polypeptide 1 - CYP26B1, Synapse differentiation inducing 1 - SYNDIG1, Transglutaminase 2 - TGM2, Dehydrogenase/reductase (SDR family) member 3 - DHRS3, Iduronate 2-sulfatase - IDS, Transketolase - TKT, Diazepam binding inhibitor - DBI, Phosphodiesterase 6 A - PDE6A, Carbonic anhydrase XI - CA11 and Paraoxonase 3 - PON3), respectively (Fig. 2D). |
| 30580964 | 0.98 | HMGCS1 (TSS -115), and FDPS (TSS -260) correspond to known sterol regulatory elements (SREs) in the respective promoter genes. |
| 31894249 | 0.98 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1), farnesyl diphosphate synthase, farnesyl-diphosphate farne-syltransferase 1 and SREBF1] was decreased (Tables SI and SIII). |
| 31540279 | 0.97 | 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (HMGCS1), 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase (MVD). |
| 0.89 | HMGCS1, HMGCR, FDPS, and MVD, which are tightly regulated by an SREBP2 transcription factor. | |
| 0.89 | HMGCS1 and FDPS, which were increased by H-RasV12, were dramatically diminished upon PD98059 treatment (Figure 4D). | |
| 31561416 | 0.97 | HMGCS1), HMG-CoA reductase (HMGCR), farnesyl diphosphate synthase (FDPS), and mevalonate diphosphate decarboxylase (MVD), for de novo cholesterol synthesis. |
| 0.78 | HMGCS1, HMGCR, MVD, FDPS, and SREBP2), fatty acid synthesis (SREBP1a and SREBP1c), and cholesterol uptake (LDL-R) in UA-treated SK-HEP-1 cells, and this UA-induced gene expression was similar to that observed with simvastatin treatment (Figure 2A). | |
| 0.51 | FDPS, HMGCR, HMGCS1, and SREBP2 was observed in UA-treated SK-HEP1 and Hep3B cells (Figure 2B). | |
| 18959802 | 0.97 | Hmgcs1), HMG CoA reductase (Hmgcr), sterol receptor binding factor-2 (Srebf2) and lanosterol 14 alpha-demethylase (Cyp51a1) (involved in cholesterol metabolism), and others including fatty acid synthase (Fasn), fatty acid binding protein (Fabp), farnesyl diphosphate synthase (Fdps), acetyl-coA carboxylase (Acaca), acetyl-coA dehydrogenase (Acadm), acetyl-coA acetyl transferase (Acat2), peroxisome proliferative activated receptor, gamma (Ppargamma) and a variety of apolipoproteins that are involved in fatty acid and triglyceride metabolism. |
| 0.82 | Hmgcs1, Srebf2, Fabp Fasn, Fdps, Acaca, Acadm, Acat2, ApoA5, C1, E and L1 as well as Cyp27a1, Ldlr, Ppargamma and Tyms (Figure 4). | |
| 18070364 | 0.97 | HMGCS1, HMGCR, IDI1, FDPS, FDFT1, NSDHL, EBP, DHCR7, INSIG1, FADS1 were upregulated by P4 exposure (Additional File 2). |
| 29670091 | 0.97 | HMGCS1, HMGCR, MVD, MVK, and FDPS, was consistently decreased after M1 virus infection in both HCT-116 and SW1990 cell lines (Fig. 1f, g). |
| 32046349 | 0.97 | HMGCoA synthase 1 (HMGCS), farnesyl diphosphate synthase (Fdps) and farnesyl-diphosphate farnesyltransferase 1 (Fdft1). |
| 20426488 | 0.96 | HMGCS1, FDPS, and FDFT1) involved in cholesterol biosynthesis (Figure 4A and Table 1). |
| 22754327 | 0.95 | HMGCS, HMGCR, farnesyl diphosphate synthase, and squalene synthase. |
| 24625837 | 0.95 | HMGCS1, HMGCR, FDPS, FDFT1 and DHCR7) involved in this pathway. |
| 29851839 | 0.95 | FDPS, HMGCS1, SQLE, ACAT2, AKR1C1, CYP1B1, AKR1B1, and PNPLA3. |
| 30578317 | 0.95 | HMGCS, HMG-CoA synthase; HMGCR, HMG-CoA reductase; DMAPP, dimethylallyl pyrophosphate; IPP, isopentenyl pyrophosphate; FPP, farnesyl pyrophosphate; FDPS, FPP synthase; SQS, squalene synthase; SM, squalene monooxygenase; LS, lanosterol synthase; GGTase-I, geranylgeranyl transferase type I. (C) Validation of SQS loss in EMC-deficient cells. |
| 25895029 | 0.94 | HMGCS1, HMGCR, MVK, IDI (both isoforms) and FDPS by IGF-1R depletion and OSI-906 treatment (Fig. 4E). |
| 22265415 | 0.93 | HMGCS1 (HR = 1.21, q = 0.007), HMGCR (HR = 1.17, q = 0.032), IDI1 (HR = 1.26, q < 0.001), FDPS (HR = 1.17, q = 0.012), SQLE (HR = 1.35, q < 0.001), LSS (HR = 1.16, q = 0.032), NSDHL (HR = 1.17, q = 0.032), DHCR7 (HR = 1.26, q < 0.001). |
| 23324130 | 0.92 | HMGCS1, FDPS and LSS and the most strongly down-regulated genes were APOE, LEPR, INSIG2, CYP51A1 and TNSF4 (Figure 4B). |
| 26095650 | 0.92 | HMGCS1 probe set 221750_at, FC = 1.1, P = 0.008), HMG-CoA reductase (HMGCR probe set 202539_s_at, FC = 4.5, P = 0.0008 and probe set 202540_s_at, FC = 1.2, P = 0.005), farnesyl diphosphate synthase (FDPS probe set 201275_at, FC = 1.1, P = 0.002), squalene synthase (FDFT1 probe set 210950_s_at, FC = 1.1, P = 0.012) and 24-dehydrocholesterol reductase (DHCR24 probe set 200862_at, FC = 1.2, P = 0.005). |
| 28962550 | 0.92 | FDPS, GPI, GSTP1, HMGCS1, NME1, PCSK9 and PKM2) and 4 down-regulated genes (ADH1C, BCL2, CASP7 and IGF1). |
| 26023727 | 0.91 | farnesyl diphosphate synthase (FDPS), 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase 1 (HMGCS1) and acetyl-CoA carboxylase beta (ACACB). |
| 31159817 | 0.90 | HMGCS1, FDPS, LSS and SQLE) and lipogenic (e.g. ACACA, SCD, FASN, FADS1 and ELOVL6) pathways. |
| 20338039 | 0.87 | HMGCS1 (cytosolic HMG-CoA synthase); HMGCR (HMG-CoA reductase); FDPS (farnesyl diphosphate synthase); FDFT1 (farnesyl-diphosphate farnesyltransferase 1, also known as squalene synthase); LDLR (low-density lipoprotein receptor). |
| 25153832 | 0.86 | FDPS, HMGCS1 and LSS were significantly upregulated. |
| 27648077 | 0.86 | HMGCS1, HMGCR, FDPS, CYP51A1, and DHCR7, were quantified by RT-qPCR analysis. |
| 25563794 | 0.76 | HMGCS, HMGCR, LDLR, farnesyl diphosphate synthase, and squalene synthase. |
| 31406127 | 0.75 | FDPS, HMGCS1, FDFT1, DHCR7 and SC5D), de novo lipogenesis (FASN and ACSS2) and phospholipid dephosphorylation (PLPP3) were upregulated in the hepatic TM6SF2 E167K spheroids, while gluconeogenesis (FBP1) was upregulated in the spheroids and downregulated in humans carrying the E167K risk variant (Fig. 6). |
| 25672394 | 0.74 | HMGCS1, MVD, IDI1, FDPS, FDFT1, CYP51, SC4MOL, NSDHL were simultaneously upregulated. |
| 20707412 | 0.73 | HMGCS1, MVD, IDI1, FDPS, FDFT1, LSS, and NSDHL). |
| 19388012 | 0.70 | 3-hydroxy-3-methylglutaryl-coA synthase 1 (HMGCS1), 3-hydroxy-3-methylglutaryl-coA reductase (HMGCR), mevalonate kinase (MVK), phosphomevalonate kinase (PMVK), diphosphomevalonate decarboxylase (MVD), isopentenyl-diphosphate delta-isomerase 1 (IDI1), farnesyl diphosphate synthase (FDPS), farnesyl-diphosphate farnesyltransferase 1 (FDFT1) and lanosterol synthase (LSS). |
| 23718831 | 0.63 | HMGCS1, HMGCR, FDPS, FDFT1 and DHCR7) were significantly increased (by 1.5-3.5 fold, Figure 4A), supporting that the elevated expression of these enzymes at protein levels occurs mainly through a transcriptional mechanism via SREBP activation. |
| 29226804 | 0.57 | FDPS, ACLY, HMGCS1, IDI1, LSS, NSDHL, and FDFT1), confirming that this is the main affected cellular pathway. |
| 27654507 | 0.52 | HMGCS1, MVK, IDI1, FDPS, FDFT1, SQLE1, LSS1, TM7SF2, and MSMO1) increased in abundance when ARID1A was induced (Table I). |
The preparation time of this page was 0.0 [sec].
